Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J. Anagnostou V, et al. Among authors: bradbury pa. Nat Med. 2023 Oct;29(10):2559-2569. doi: 10.1038/s41591-023-02598-9. Epub 2023 Oct 9. Nat Med. 2023. PMID: 37814061 Free PMC article. Clinical Trial.
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA. Laurie SA, et al. Among authors: bradbury pa. Eur J Cancer. 2014 Mar;50(4):706-12. doi: 10.1016/j.ejca.2013.11.032. Epub 2013 Dec 17. Eur J Cancer. 2014. PMID: 24360368 Clinical Trial.
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG; Australasian Lung Cancer Trials Group; NCI Naples Clinical Trials Unit. Ellis PM, et al. Among authors: bradbury pa. Lancet Oncol. 2014 Nov;15(12):1379-88. doi: 10.1016/S1470-2045(14)70472-3. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439692 Clinical Trial.
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, Bradbury PA. Bar J, et al. Among authors: bradbury pa. Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002. Epub 2015 May 13. Clin Lung Cancer. 2015. PMID: 26081815 Clinical Trial.
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Foster NR, et al. Among authors: bradbury pa. J Thorac Oncol. 2015 Jul;10(7):1099-106. doi: 10.1097/JTO.0000000000000548. J Thorac Oncol. 2015. PMID: 26134227 Free PMC article. Clinical Trial.
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA. Zer A, et al. Among authors: bradbury pa. J Thorac Oncol. 2016 Mar;11(3):312-23. doi: 10.1016/j.jtho.2015.11.010. Epub 2015 Dec 31. J Thorac Oncol. 2016. PMID: 26749487 Free article.
109 results